NZ527173A - Specific human antibodies for selective cancer therapy - Google Patents

Specific human antibodies for selective cancer therapy

Info

Publication number
NZ527173A
NZ527173A NZ527173A NZ52717301A NZ527173A NZ 527173 A NZ527173 A NZ 527173A NZ 527173 A NZ527173 A NZ 527173A NZ 52717301 A NZ52717301 A NZ 52717301A NZ 527173 A NZ527173 A NZ 527173A
Authority
NZ
New Zealand
Prior art keywords
human antibodies
cancer therapy
specific human
selective cancer
chain variable
Prior art date
Application number
NZ527173A
Other languages
English (en)
Inventor
Yocheved Hagai
Janette Lazarovits
Rachel Guy
Orly Lipschitz
Esther Szanthon
Avigdor Levanon
Daniel Plaksin
Tuvia Peretz
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of NZ527173A publication Critical patent/NZ527173A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ527173A 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy NZ527173A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049440 WO2002059264A2 (fr) 2000-12-29 2001-12-31 Anticorps humains specifiques pour la therapie selective du cancer

Publications (1)

Publication Number Publication Date
NZ527173A true NZ527173A (en) 2006-03-31

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527173A NZ527173A (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Country Status (15)

Country Link
EP (1) EP1353937A4 (fr)
JP (1) JP2004524023A (fr)
KR (1) KR20030091952A (fr)
CN (1) CN100374456C (fr)
AU (1) AU2002246737B2 (fr)
BR (1) BR0116763A (fr)
CA (1) CA2433227A1 (fr)
CZ (1) CZ20031983A3 (fr)
HU (1) HUP0400775A2 (fr)
IL (1) IL156690A0 (fr)
MX (1) MXPA03005944A (fr)
NZ (1) NZ527173A (fr)
PL (1) PL365758A1 (fr)
RU (1) RU2316564C2 (fr)
WO (1) WO2002059264A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279657A1 (en) * 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
AU2004256113A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
EP2373343B1 (fr) * 2008-12-19 2015-02-11 Philogen S.p.A. Immunocytokines pour thérapie tumorale avec agents chimiothérapiques
NZ604805A (en) * 2010-07-09 2014-09-26 Affibody Ab Polypeptides
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
HRP20211889T1 (hr) * 2014-10-23 2022-03-04 Singh Molecular Medicine, Llc Antitijela sa jednom domenom usmjerena protiv intracelularnih antigena
EP3233122A4 (fr) * 2014-12-17 2018-09-19 Intrexon Corporation Fragments variables intercalés à chaîne unique
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
US20180305432A1 (en) * 2015-10-01 2018-10-25 Ospedale San Raffaele S.R.L. Tcr and uses thereof
EP3903818A1 (fr) * 2015-11-19 2021-11-03 Revitope Limited Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables
IL290517B1 (en) * 2016-09-14 2024-08-01 Teneobio Inc CD3 binding antibodies
KR20230140553A (ko) * 2020-11-13 2023-10-06 프로메테우스 바이오사이언시즈, 인크. Tl1a를 표적으로 하는 염증성 질환의 치료를 위한 방법, 시스템, 및 키트

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
EP0988056B1 (fr) * 1997-01-22 2003-07-09 Board Of Regents, The University Of Texas System Methodes et compositions de thromboplastine tissulaire pour le traitement de la coagulation et des tumeurs

Also Published As

Publication number Publication date
KR20030091952A (ko) 2003-12-03
CZ20031983A3 (cs) 2005-07-13
EP1353937A4 (fr) 2005-04-13
HUP0400775A2 (en) 2007-05-02
PL365758A1 (en) 2005-01-10
JP2004524023A (ja) 2004-08-12
MXPA03005944A (es) 2005-04-29
IL156690A0 (en) 2004-01-04
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
EP1353937A2 (fr) 2003-10-22
CN1551886A (zh) 2004-12-01
CA2433227A1 (fr) 2002-08-01
WO2002059264A3 (fr) 2003-03-06
BR0116763A (pt) 2004-03-09
WO2002059264A2 (fr) 2002-08-01
RU2316564C2 (ru) 2008-02-10
RU2003123100A (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
NZ527173A (en) Specific human antibodies for selective cancer therapy
ATE218890T1 (de) Bispezifische moleküle mit klinischer verwendbarkeit
AU2003278002A1 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
NZ332566A (en) Antigen binding fragments that specifically detect cancer cells
HK1076128A1 (en) Humanized collagen antibodies and related methods
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
IL200404A (en) Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer
EA201100128A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
WO1997046589A3 (fr) Anticorps humanises se liant au meme antigene que celui lie par l'anticorps nr-lu-13 et leur utilisation dans des procedes de preciblage
ATE265532T1 (de) Monoklonaler antikörper br110 und dessen anwendung
HK1072272A1 (en) Anti-ccr5 antibody
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
EP1881064A3 (fr) Anticorps monoclonaux HCV-anti-cýur
DE60033455D1 (de) Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie
EP1581096A3 (fr) Antigene pipa et anticorps de liaison a celui-ci
EP1491555A4 (fr) Gene a region variable de chaine legere/lourde d'anticorps monoclonal hab18 anti-hepatome humain
AU3587599A (en) Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
AU2003226127A1 (en) Antibody libraries
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
WO2004050849A3 (fr) Immunotoxine recombinante et son utilisation dans le traitement de tumeurs
WO2005070456A3 (fr) Diagnostic et traitement du cancer
WO2003072727A3 (fr) Anticorps monoclonaux specifiques d'egfrviii, ribozymes d'egfrviii et utilisations en detection, traitement ou prevention de cancer associe a l'egfrviii
EP2641611A3 (fr) Thérapie combinée
WO2005049652A3 (fr) Procede de generation in vitro d'une diversite d'anticorps

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed